Clinical Trial Update: Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years) [Phase 3]

View source ↗

Summary

Phase 3 pediatric study assessing migalastat safety, pharmacokinetics/pharmacodynamics, and efficacy in adolescents with Fabry disease has completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• Migalastat (migalastat)

Snippet

Sponsor: Amicus Therapeutics | Conditions: Fabry Disease | Phase 3 | Status: COMPLETED | Results posted: 2021-11-30